尼可地尔对PCI术后心绞痛患者疗效及丙二醛与脂联素水平的影响

Therapeutic efficacy of nicorandil on angina pectoris after PCI and its influence on the levels of malondialdehyde and adiponectin

【目的】研究尼可地尔对经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后心绞痛患者的疗效以及对丙二醛(malondialdehyde,MDA)与脂联素(adiponectin,APN)水平的影响。【方法】选取2011年1月至2016年2月来我院心内科接受PCI治疗的冠心病患者150例为研究对象,按照随机数字表法分为研究组和对照组,各75例。PCI术后,对照组采用冠心病二级预防,研究组在对照组基础上予给予尼可地尔治疗,分析比较两组患者临床疗效、MDA和APN水平。【结果】研究组临床总有效率显著高于对照组(93.3%vs 81.4%,P<0.05)。治疗后,研究组MDA水平显著低于对照组[(5.86±1.12)nmol/L vs(7.36±1.13)nmol/L,P<0.05],APN水平显著高于对照组[(3.62±0.63)ng/L vs(2.71±0.58)ng/L,P<0.05]。【结论】尼可地尔治疗PCI术后心绞痛疗效显著,能够有效降低丙二醛水平,提高脂联素水平,安全可靠。

[Objective]To study the therapeutic efficacy of nicorandil on angina pectoris after percutaneous coronary intervention （PCI） and it influence on the levels of malondialdehyde （MDA） and adiponectin （APN）. [ Methods ] A total of 150 patients with coronary heart disease undergoing PCI in our hospital from January 2011 to February 2016 were selected as the research subjects and randomly divided into the study group and control group, 75 cases per group. After PCI, the patients in the control group were treated with secondary prevention of coronary heart disease, and those in the study group were given nicorandil on the therapy basis of the control group. The clinical efficacy, levels of MDA and APN were compared between the two groups. [ Results] The total effective rate in the study group was significantly higher than that in the control group （93.3% VS 81.4%, P 〈 0.05）. After the treatment, the level of MDA in the study group was significantly lower than that in the control group [（5.86 ± 1.12）nmol/L VS（7.36 ± 1.13）nmol/L, P〈 0.05]; the level of APN was significantly higher than that in the control group [（3.62 ± 0.63）ng/L VS （2.71 ±0.58） ng/L, P〈 0.05]. [Conclusion] The therapeutic efficacy of nicorandil on angina pectoris after PCI is significant. It can effectively reduce the MDA level and improve the APN level. It is safe and reliable.